Report: 1 in 5 will rebound after Paxlovid, but it still works
By
Kristen Fischer
Nov 14, 2023
One in five people who take nirmatrelvir/ritonavir (Paxlovid) get COVID-19 again after the drug clears them of it, according to a new study.
Unforeseen consequences pile up in race to find COVID-19 treatments
By
Alicia Lasek
Mar 25, 2020
The national attention gained by an experimental drug and two existing medications has led to unintended trouble for patients.
Merck to seek emergency use for COVID-19 antiviral pill that cuts severe outcomes by 50 percent
By
Alicia Lasek
Oct 04, 2021
Molnupiravir has reduced COVID-19 deaths and hospitalizations by half in a new clinical trial. An orally delivered drug could offer unprecedented treatment convenience, the drug’s developers say.
Wearable tech offers hope for spotting dementia-causing diseases
By
Kristen Fischer
Mar 08, 2024
Wearable technology that measures spatial navigation and gait could improve detection of diseases that cause dementia, according to a new study.
Alzheimer’s cure would mean $16B in lost revenues for assisted living
By
Lois A. Bowers
Sep 17, 2019
A cure for Alzheimer’s disease would be a “medical miracle” but would result in a loss of $16.3 billion in assisted living annual revenues.
Paxlovid cuts COVID hospitalization, which may leave older adults weakened
By
Alicia Lasek
Dec 02, 2022
The CDC reports that COVID patients treated with the antiviral Paxlovid have a 51% lower risk of hospitalization, while another study has tied acute-care stays to muscle loss and long COVID.
LTC vaccinators opt to briefly halt J&J shots while awaiting FDA guidance
By
Alicia Lasek
Apr 14, 2021
Long-term care pharmacies and clinicians have temporarily paused their use of Johnson & Johnson’s COVID vaccine following recommendations from health officials. Guidance is needed quickly in order to...
Makers of newer vaccines tout advantages as trial results and approvals announced
By
Alicia Lasek
Feb 01, 2021
Two drugmakers say their vaccines, which include J&J’s one-dose candidate, are effective against new coronavirus variants, while AstraZeneca’s vaccine is now approved for adults across the...
Providers call for broader antipsychotic exclusions to help reduce schizophrenia diagnoses
By
Kimberly Marselas
Mar 31, 2023
Providers and quality experts are questioning why the agency hasn’t done more to review its quality measure for antipsychotic drug use.
Opt-in COVID vaccine program kicks off; Feds partner with CVS, Walgreens
By
Alicia Lasek
Oct 19, 2020
Long-term care facilities nationwide can voluntarily opt in to a free pharmacy partnership program that will provide and administer future COVID-19 vaccines on site, federal officials announced Friday.